City

Changsha (1)

Ghent (1)

Seoul (1)

Condition

Prevention of Influenza (3)

Overall Status

Completed (2)

Not yet recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 3 (1)

phase 4 (1)

Sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1)

SK Chemicals Co., Ltd. (1)

University Hospital, Ghent (1)

Collaborator

CEVAC Core Lab, University Ghent (1)

Max Planck Institute for Infection Biology (MPIIB), Berlin, Germany (1)

VisMederi srl, Sienna, Italy (1)

deCODE genetics, Iceland (1)

Intervention

active compared vaccine (1)

agrippal (1)

investigational vaccine(0.25ml/vial) (1)

investigational vaccine(0.5ml/vial) (1)

nbp607 (1)

seasonal,quadrivalent,influenza vaccine (1)

Study Documents

Intervention Type

biological (2)

drug (1)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

prevention of influenza

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Prevention of Influenza Trial in Changsha (Investigational Vaccine(0.25ml/vial), Investigational Vaccine(0.5ml/vial), Active

Not yet recruiting

Prevention of Influenza

Investigational Vaccine(0.25ml/vial)
+2 more

Changsha, Hunan, China

Hunan Provincial Center for Disease Control and Prevention

Dec 6, 2022

Prevention of Influenza Trial in Ghent (Seasonal,quadrivalent,influenza vaccine)

Completed

Prevention of Influenza

Seasonal,quadrivalent,influenza vaccine

Ghent, East-Flanders, Belgium

University Hospital - Center for Vaccinology

Jan 21, 2022

Prevention of Influenza Trial in Seoul (NBP607, Agrippal)

Completed

Prevention of Influenza

NBP607
Agrippal

Seoul, Guro-gu, Korea, Republic of

Korea University Guro Hospital

Mar 25, 2019